Dupilumab is a human monoclonal antibody targeting the Th2 immune axis by inhibiting IL-4 and IL-13 and has shown efficacy for moderate to severe atopic dermatitis and sporadic cases of NE in adults [2,5]. Here, IL13 is linked to atopic eczema.